Literature DB >> 18625649

Circulating thrombomodulin and vascular cell adhesion molecule-1 and renal vascular lesion in patients with lupus nephritis.

G H Yao1, Z H Liu, X Zhang, C X Zheng, H P Chen, C H Zeng, L S Li.   

Abstract

Currently, the detection of renal vascular lesions (VLS) in lupus nephritis (LN) mainly depends on biopsy examination, and lack surrogate biomarkers for clinical dynamic evaluation. The aim of the present study is to explore the correlation between circulatory endothelial damage biomarkers and VLS. Soluble E-selectin, thrombomodulin (TM) and vascular cell adhesion molecule-1 (VCAM-1) were measured by ELISA. TM and VCAM-1 levels both were significantly elevated in LN with VLS than in LN without VLS (P < 0.01). However, the serum E-selectin was not significantly changed in LN patients with and without VLS. A positive correlation was found between TM and serum creatinine (r = 0.617, P < 0.05) in patients with vascular lesions. In order to further analyse the relationship between TM level and severity degree of vascular lesions in LN patients, we subdivided the patients with vascular lesions into two groups: with thrombotic microangiopathy (TMA) and without TMA. TM level of the patients with TMA is significantly higher than those without TMA (P < 0.01). In conclusion, combined with renal pathological examination, monitoring the circulatory levels of TM and VCAM-1, can provide circulating biomarkers of VLS in LN patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625649     DOI: 10.1177/0961203308089441

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.

Authors:  Juan M Mejia-Vilet; Samir V Parikh; Huijuan Song; Paolo Fadda; John P Shapiro; Isabelle Ayoub; Lianbo Yu; Jianying Zhang; Norma Uribe-Uribe; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2019-07-01       Impact factor: 5.992

2.  Evaluation of clinical outcomes and renal vascular pathology among patients with lupus.

Authors:  Claire Barber; Andrew Herzenberg; Ellie Aghdassi; Jiandong Su; Wendy Lou; Gan Qian; Jonathan Yip; Samih H Nasr; David Thomas; James W Scholey; Joan Wither; Murray Urowitz; Dafna Gladman; Heather Reich; Paul R Fortin
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 8.237

3.  Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.

Authors:  Jennifer M P Woo; Zhuofeng Lin; Mohamad Navab; Casey Van Dyck; Yvette Trejo-Lopez; Krystal M T Woo; Hongyun Li; Lawrence W Castellani; Xuping Wang; Noriko Iikuni; Ornella J Rullo; Hui Wu; Antonio La Cava; Alan M Fogelman; Aldons J Lusis; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

Review 4.  Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.

Authors:  Aikaterini Arida; Athanasios D Protogerou; George D Kitas; Petros P Sfikakis
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

5.  Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis.

Authors:  Huihua Ding; Yiwei Shen; Cheng Lin; Ling Qin; Shijun He; Min Dai; Shinji L Okitsu; Julie A DeMartino; Qiang Guo; Nan Shen
Journal:  Arthritis Res Ther       Date:  2022-03-28       Impact factor: 5.156

6.  Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk.

Authors:  Maria José Santos; Diana Carmona-Fernandes; Helena Canhão; José Canas da Silva; João Eurico Fonseca; Victor Gil
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.